research Disproportionality analysis comparing safety profiles of sonidegib and vismodegib based on the FAERS database
Sonidegib and vismodegib have different side effects and reporting patterns.
Search
for
Sort by
Research
30 / 181 results
research A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
Pexidartinib often causes liver issues and fatigue, especially in women.
research Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database
Finasteride use is linked to increased reports of cognitive problems, especially in younger people with hair loss.
research A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
Avacopan may cause unexpected side effects, so early monitoring is important.
research Spectrum and signals of medication-associated cognitive disorder: a comprehensive disproportionality analysis with cross-database validation
Many medications may be linked to cognitive disorders, but most lack warnings on labels.
research Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
Ixekizumab has known and some unexpected side effects.
research Assessing the safety of topical minoxidil through disproportionality analysis of FAERS reports
Topical minoxidil may cause more side effects than currently listed, needing updated safety information.
research Cardiovascular Safety Signals of Oral Versus Topical Minoxidil in FAERS: A Disproportionality Analysis (Analytic Cohort 2012–2025)
Oral minoxidil may have more cardiovascular risks than topical minoxidil.
research Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System
Oral finasteride may cause more sexual side effects than expected, possibly due to negative publicity and reporting bias.
research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
research Drug-associated gingival disorders: a retrospective pharmacovigilance assessment using disproportionality analysis
Certain medications can cause gum problems, so patients and healthcare providers should be aware and monitor oral health.
research Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database
Some drugs used to treat inflammation may cause hair loss.
research Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions—A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data
Incretin-based drugs for obesity often cause gastrointestinal issues, with tirzepatide having the most reports.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
Finasteride may be linked to Peyronie’s disease, but more research is needed.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
research Response to: “finasteride prescribed for hair loss consistently leads to depression”
Finasteride does not consistently cause depression.
research 222 Pharmacovigilance Analysis of Reports of Sexual Dysfunction Associated with Finasteride Use: Implications for the Post-Finasteride Syndrome
Finasteride is linked to sexual dysfunction, especially in younger users treating hair loss.
research 017 Pharmacovigilance Analysis of Reports of Sexual Dysfunction Associated with Finasteride Use: Implications for the Post-Finasteride Syndrome
Finasteride is linked to sexual dysfunction, especially in younger men using it for hair loss.
research PD20-08 INVESTIGATION OF SEXUAL DYSFUNCTION LINKED TO FINASTERIDE USE: A PHARMACOVIGILANCE ANALYSIS
Finasteride use is strongly linked to sexual dysfunction, especially in young men treating hair loss.
research Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
Statins may be linked to reproductive organ conditions, and their risks should be monitored.
research Reframing the Discussion on Finasteride and Neuropsychiatric Safety
Finasteride is not proven to cause depression or suicide, and careful patient monitoring is advised.
research Machine Learning--Enhanced Pharmacovigilance Assessment of Cardiac Adverse Events Associated With Minoxidil
Minoxidil is strongly linked to heart problems, and machine learning can improve drug safety checks.
research Analysis of chemotherapy-induced peripheral neuropathy using the Japanese Adverse Drug Event Report database
Certain cancer drugs are strongly linked to nerve damage, requiring close monitoring and early treatment.
research Drug-induced vitiligo: a real-world pharmacovigilance analysis of the FAERS database
Certain drugs may cause vitiligo, so patients should be monitored.
research Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database
Biologics for severe asthma have known side effects, but some new risks need more study.
research Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017
HPV vaccines are generally safe but need further investigation for rare side effects.
research Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
Finasteride can cause long-term side effects like sexual dysfunction and depression.
research Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database
Ipilimumab can cause various adverse events in elderly patients, especially affecting the gastrointestinal and endocrine systems.